Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
None
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

daily for 7 days or longer. Bortezomib, or Velcade , is given for a few seconds by a rapid push through a needle into the vein. It is given twice weekly for four doses and then stopped for 1 week

herpes
chemotherapy regimen
bortezomib
neutrophil count
rituximab
  • 57 views
  • 10 Nov, 2021
  • 1 location
None
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

not eligible for autologous stem cell transplantation (ASCT): bortezomib-melphalan-prednisone (VMP), melphalan-prednisone- thalidomide (MPT) and lenalidomide with low-dose dexamethasone (Rd).

lenalidomide
melphalan
bone lesion
bortezomib
calcium
  • 4 views
  • 10 May, 2021
  • 1 location
None
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.

lenalidomide
daratumumab
chemotherapy regimen
high dose chemotherapy
bone lesion
  • 3 views
  • 18 Oct, 2021
  • 1 location
None
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenstrm's macroglobulinemia (Ballondor trial)

lenalidomide
rituximab
bortezomib
measurable disease
dexamethasone
  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)

lenalidomide
dexamethasone
bortezomib
  • 0 views
  • 27 Aug, 2021
  • 1 location
None
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

lenalidomide
refractory multiple myeloma
bone marrow procedure
measurable disease
cancer
  • 0 views
  • 17 Oct, 2021
  • 9 locations
None
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I Stage II or Stage III Multiple Myeloma

RATIONALE: Drugs used in chemotherapy, such as melphalan, use different ways to stop cancer cells from dividing so they stop growing or die. Stem cell transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Giving …

  • 19 views
  • 07 Nov, 2020
  • 3 locations
None
Ixazomib Lenalidomide and Combination for Maintenance in NDMM Patients

The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.

lenalidomide
maintenance therapy
ixazomib
  • 1 views
  • 24 Jan, 2021
  • 1 location
None
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients. The only potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed …

lenalidomide
leukemia
melphalan
bortezomib
plasma cell leukemia
  • 65 views
  • 05 Feb, 2021
  • 3 locations
None
A Phase 1 Study of Ruxolitinib Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

lenalidomide
bone lesion
plasmacytosis
neutrophil count
monoclonal protein
  • 36 views
  • 24 Jan, 2021
  • 10 locations